NasdaqGS:IDYABiotechs
Should IDEAYA’s DLL3 Combo Trial and Early IDE849 Signals Prompt a Rethink From IDYA Investors?
IDEAYA Biosciences recently reported first-patient-in for a global Phase 1 trial combining IDE849, a DLL3-targeting Topo-I ADC, with its PARG inhibitor IDE161 in DLL3-upregulated solid tumors such as small cell lung cancer, neuroendocrine tumors, and melanoma.
An interesting aspect is the early Phase 1 signal of multiple partial responses for IDE849, including in small cell lung cancer patients previously treated with IMDELLTRA®, highlighting the potential of this mechanistically distinct...